Sol-Gel Technologies Ltd.
General ticker "SLGL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $171.1M (TTM average)
Sol-Gel Technologies Ltd. follows the US Stock Market performance with the rate: 27.6%.
Estimated limits based on current volatility of 3.1%: low 64.83$, high 68.97$
Factors to consider:
- Total employees count: 28 (-17.6%) as of 2025
- Current price 65.4% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [14.89$, 38.84$]
- 2026-12-31 to 2027-12-31 estimated range: [8.74$, 24.29$]
Financial Metrics affecting the SLGL estimates:
- Negative: with PPE of -19.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of 0.27 <= 2.37
- Negative: 69.38 < Shareholder equity ratio, % of 76.25 <= 81.92
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
Short-term SLGL quotes
Long-term SLGL plot with estimates
Financial data
| YTD | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Operating Revenue | $11.54MM | $19.39MM |
| Operating Expenses | $23.55MM | $26.93MM |
| Operating Income | $-12.01MM | $-7.54MM |
| Non-Operating Income | $1.43MM | $1.41MM |
| R&D Expense | $17.80MM | $22.80MM |
| Income(Loss) | $-10.58MM | $-6.13MM |
| Net Income(Loss)* | $-10.58MM | $-6.13MM |
| Stockholders Equity | $28.85MM | $22.81MM |
| Assets | $35.85MM | $29.92MM |
| Operating Cash Flow | $-13.89MM | $0.32MM |
| Capital expenditure | $0.00MM | $0.05MM |
| Investing Cash Flow | $26.69MM | $-8.58MM |
| Financing Cash Flow | $0.00MM | $0.01MM |
| Earnings Per Share** | $-3.80 | $-2.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.